Navegando por Assunto "Duloxetina"

Agora exibindo 1 - 2 de 2

Acesso aberto (Open Access)
Avaliação pré-clínica da duloxetina em modelo de convulsão: análise comportamental, eletroencefalográfica e influência no estresse oxidativo
(Universidade Federal do Pará, 2014-06-17) COELHO, Danielle Santana; CRESPO LÓPEZ, Maria Elena; http://lattes.cnpq.br/9900144256348265
Epilepsy is a disorder with high prevalence and severity. Although there are several anticonvulsant drugs available in the market, 30 to 40% of the patients are refractory to the treatment. Besides the seriousness of epilepsy per se, this disorder may be accompanied by many comorbidities such as depression, which is the main psychiatric comorbidity of epilepsy. The mechanisms involved in the relationship between epilepsy and depression are not clarified. Given that some anticonvulsant drugs can trigger or enhance depressive symptoms, while some antidepressant drugs can potentiate the severity of seizure, the concomitant treatments of both disorders can be problematic. On the other hand, some studies have shown that antidepressant drugs can be safe and even possess an anticonvulsant activity such as venlafaxine, a serotonin and noradrenaline reuptake inhibitor (SNRI). Considering that duloxetine, another SNRI, has a more potent inhibition of monoaminergic transporters and that there is no study about its influence on seizures, the aim of our study is to verify the potential anticonvulsant action of duloxetine against seizures induced by pentylenetetrazole (PTZ) on mice. With this aim, mice will be pre-treated with duloxetine (10, 20, 40 mg/kg/i.p.), and thirty minutes after, the animals will receive an intraperitoneal injection of PTZ (60 mg/kg, i.p.). In the following twenty minutes the animals are going to be evaluated. The threshold for the first myoclonic jerk, tonic-clonic seizure, the duration of seizures and survival will be quantified. The electroencephalographic analysis (EEG) was used to assess the severity of the seizures (wave’s amplitude increase). After this period the animals will be sacrificed, the cerebral cortex dissected and biochemical analysis (activity of superoxide dismutase (SOD), catalase (CAT), nitrite levels and lipid peroxidation) will be made to investigate the mechanisms by which this drug can influence seizures. The results exhibit the anticonvulsant action of duloxetine. The drug was capable of enhancing the threshold for the first myoclonic and tonic-clonic seizures induced by PTZ. Additionally, the EEG demonstrated that duloxetine at the dose of 20 mg/kg decreased significantly the amplitude of the waves while at the dose of 40 mg/kg it increased the amplitude when compared to all the treatments. Regarding the evaluation of duloxetine’s influence on oxidative stress, all the animals treated solely with PTZ presented a significant increase on lipid peroxidation and a decrease on SOD and CAT activity. Concerning nitrites’ level, there was no difference between the treatments. The dose of 20 mg/kg of duloxetine showed a significant protection against the alterations in oxidative stress induced by PTZ. The anticonvulsant action of duloxetine (20 mg/kg) collaborates with the theory which has been presented in the last few years where it is proposed that the modulation of the serotonergic and noradrenergic neurotransmission may exert an anticonvulsant activity. Moreover, the efficiency of duloxetine in preventing the aggravation of oxidative stress involved in the seizures induced by PTZ corroborates with studies that demonstrate that anticonvulsant substances can influence seizures through its antioxidant activity. Given these points, we conclude that duloxetine is a promising adjuvant for the treatment of patients with the comorbidity epilepsy and depression.
Acesso aberto (Open Access)
Genotoxicidade humana e fármacos antidepressivos: avaliação da duloxetina em culturas de linfócitos
(Universidade Federal do Pará, 2014-05-29) ARAÚJO, Daniella Bastos de; CRESPO LÓPEZ, Maria Elena; http://lattes.cnpq.br/9900144256348265
Antidepressants are widely used for the symptomatic treatment of depressive disorder. Numerous current research on depression has contributed to the advancement of drug therapy and the emergence of new antidepressant drugs. Current guidelines for genotoxicity testing of new drugs suggests the important utility of assays that detect DNA damage, or tests to evaluate the induction of DNA breakage. However, the small number of data on the genotoxicity of drugs causes the number of drugs that can actually be used safely is reduced. Therefore, it is of utmost importance genotoxicology studies on the evaluation of drugs, especially drugs used for a long period of time such as antidepressants. Duloxetine is a new antidepressant belonging to the class of selective serotonin reuptake inhibitors of serotonin and norepinephrine (SNRIs), used in the symptomatic treatment of depression. Despite the existence of studies showing that some antidepressant drugs are genotoxic, there is to date no study on the possible genotoxicity of duloxetine in human cells. Thus, this study aims to explore the possible genotoxic potential of duloxetine in vitro in primary cultures of human lymphocytes through the techniques of detection of chromosomal aberrations and micronuclei. Primary cultures of blood lymphocytes of healthy volunteers were exposed to different concentrations of duloxetine (10-150 ng/ml) and cyclophosphamide (6 μg/ml) as a positive control. Structural chromosomal aberrations, mitotic index, nuclear division index, index binucleation, number of cells with one, two, three and four micronuclei and the number of cells with nucleoplasmáticas bridges were evaluated. All cultures incubated with indices of duloxetine were significantly lower than those of the control groups, indicating a degree of cytotoxicity of the drug. However, only concentrations of 100 and 150 ng/ml caused a significant increase in the presence of chromosomal aberrations and micronuclei. Whereas these concentrations are close to the upper limit of the therapeutic range of the drug used in humans, our results call already on the need to deepen their understanding of human genotoxicity of duloxetine.